BIOVAXYS ANNOUNCES LIFE OFFERING

Executive Summary

• BioVaxys Technology Corp. announced a non‑brokered private placement (“Offering”) of up to 9,411,764 units at $0.17 per unit, targeting gross proceeds of up to $1.6 million (minimum $1.2 million).
• Each unit consists of one common share and one warrant to purchase an additional share at $0.40 exercisable for 24 months.
• Proceeds will be used to advance the company’s organic pipeline, including licensing collaborations, pre‑clinical DPX supply, food‑allergy program initiation, patent activities, and data analysis from MVP‑S Phase 1 studies.

Key Details

• Units Offered: Minimum 7,058,824 units; maximum 9,411,764 units.
• Issue Price: $0.17 per unit.
• Gross Proceeds: Minimum $1,200,000; up to $1,600,000.
• Unit Composition:
• 1 common share of BioVaxys.
• 1 common share purchase warrant (exercise price $0.40, valid for 24 months).
• Closing Timeline: Expected on or before 45 days after the release date, subject to regulatory approvals (including CSE acceptance).
• Use of Proceeds:
  1. Pursue multiple licensing opportunities and research collaborations with DPX technology.
  2. Identify/produce GLP‑grade non‑GMP preclinical supply of DPX for peanut allergy vaccine program and expand DPX formulations to mRNA & neoantigens.
  3. Initiate DPX food‑allergy program at McMaster University (preclinical proof‑of‑concept for DPX peanut antigen prophylaxis).
  4. File new patents and pay annuities on issued patents.
  5. Complete immunological data analysis from MVP‑S Phase 1 studies to prepare assets for out‑licensing in additional tumor types.
• Exemption Basis: Listed Issuer Financing Exemption under Part 5A of NI 45‑106; securities not subject to a hold period in Canada (except Quebec).
• Finder’s Fees: Company may pay eligible finders who introduce subscribers.
• Documentation: Offering document dated Oct 7 2025 available on SEDAR+ and the company website.

Notable Quotes

• “The proceeds from this offering will accelerate our pipeline growth, enabling us to expand licensing collaborations, advance pre‑clinical programs, and move critical data packages toward out‑licensing opportunities,” – James Passin, CEO.